Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy - Wikidata - wikimedia - TriplyDB

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

http://www.wikidata.org/entity/Q30899557

about

Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles Virotherapy: cancer gene therapy at last?Trial Watch-Oncolytic viruses and cancer therapy Gene Therapy 2017: Progress and Future Directions.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer.A century of oncolysis evolves into oncolytic immunotherapy.The oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Phase 1 Study of Intravenous Oncolytic Poxvirus (vvDD) in Patients With Advanced Solid Cancers.Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy.Arming oncolytic viruses to leverage antitumor immunity.Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.Synergistic antitumor activity of triple-regulated oncolytic adenovirus with VSTM1 and daunorubicin in leukemic cells.Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy.Oncolytic viruses: emerging options for the treatment of breast cancer.Predictive and Prognostic Clinical Variables in Cancer Patients Treated With Adenoviral Oncolytic Immunotherapy.Tumor-Localized Secretion of Soluble PD1 Enhances Oncolytic Virotherapy.Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity.Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.Potent antitumor effect of tumor microenvironment-targeted oncolytic adenovirus against desmoplastic pancreatic cancer.Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Showing the Way: Oncolytic Adenoviruses as Chaperones of Immunostimulatory Adjuncts.Oncograms Visualize Factors Influencing Long-Term Survival of Cancer Patients Treated with Adenoviral Oncolytic Immunotherapy.

P2860

Q26739777-98E4F5D9-D90B-403D-A459-0D1A2C7B40D2 Q26777403-C3FBA70A-101C-4EF9-832A-678D4B622B28 Q28066228-18F0C6D3-EAF9-45AC-BF5B-F646A64262CF Q28072347-A4922A5F-8775-4256-B88A-FBD46C4F6FB6 Q33891559-C7328553-114B-4622-8CDB-D0A4B719CAA3 Q36301061-997B8EA0-BAA1-495F-8238-F22A83E7180A Q36582785-8F67B904-9A20-48F2-A0F5-23C7E764514D Q36710972-9D3144D9-0ACA-40F0-9FB9-092BEF3063E3 Q36710991-90916B17-6031-4A3D-B01E-A4B249E5DEDD Q36738884-2571415D-DB59-4888-91CA-711EB6F25049 Q36757131-880F1809-DC17-434B-B762-04D7EFE063A9 Q37256174-C3F61BCC-AF4F-4713-937F-C7DF518761F1 Q37718529-9765B34E-21F6-4F5E-A4C2-109436270120 Q38470166-8972444A-34D6-4F22-BA82-1B2B799026B5 Q38645128-4666E06D-5891-433A-BBB8-8B3BA4606E8B Q38754849-6BCA4CA8-9814-42BB-8196-AA3D3F2A9D4D Q38875030-EAA33E68-99BC-40D9-8C6E-768C681458A3 Q39129326-02D77BEF-5C97-475A-B1B6-5651B53E0171 Q39868041-89ABDB14-19C2-46E5-8059-81B45DD96979 Q40287020-FB55992E-4C19-439E-B345-A4F747EB49C5 Q40607907-8C0B4E35-31FD-4A3E-9BDC-74E06F9FAA51 Q40674940-60B99896-658D-4E4A-951F-A86877F9A612 Q41934085-6C95491A-C1C6-43EC-A4DA-76C57EA1FA8D Q41963078-66949A90-CEBF-484D-899D-033ACC887B3D Q42695310-BF508151-BC53-4BD0-BE01-592131DF7230 Q47141309-F11223D1-B667-45D8-82ED-53FE405DC2C4 Q53883435-9FE03FCF-1F88-42B9-8DDE-BC65A67D3C95 Q55510561-C5E02072-C6CE-465F-A23D-F418BF68E334

P2860

Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy

http://www.wikidata.org/entity/Q30899557

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Immunological data from cancer ...... tility for tumor immunotherapy

@ast

Immunological data from cancer ...... tility for tumor immunotherapy

@en

type

label

Immunological data from cancer ...... tility for tumor immunotherapy

@ast

Immunological data from cancer ...... tility for tumor immunotherapy

@en

prefLabel

Immunological data from cancer ...... tility for tumor immunotherapy

@ast

Immunological data from cancer ...... tility for tumor immunotherapy

@en

P1433

Q30899557-FE7E162A-4167-4EBE-96C1-C950B7F93E53

P1476

Q30899557-041B1DE8-382E-47FB-8690-79A2280CCD0A

P2093

Q30899557-2AA943FD-1720-4DA2-9803-577DC9FCDD07

Q30899557-35745797-9FA0-4310-B33F-92EF46EEE23E

Q30899557-59086984-08B7-4F06-A45D-3085E346AAFA

Q30899557-712712CB-0787-4F25-88C2-2077D245FB54

Q30899557-B4992F95-5D1A-4A30-B085-78A6366DCDA8

Q30899557-C92537D5-134B-484E-9F06-0AA6CC7988F7

Q30899557-E690EBAA-1915-439B-91BE-5FBEEC8C460C

Q30899557-F077CF75-66A6-4B09-B180-6BA480826CD2

Q30899557-F3EEB8ED-A6CD-4F78-A550-C8DD5ED70AE6

Q30899557-FF9E97C4-C845-4851-B643-902FC9ACC6E7

P2860

Q30899557-0653977D-CF30-44E9-A317-9808E6CD4ED5

Q30899557-240CC1C4-6F53-490C-97C8-7BD76AA76981

Q30899557-2943803A-D78F-466F-A326-2021E57FD22E

Q30899557-2D2169F9-B560-470D-A5AE-E53A492414CE

Q30899557-2FEBBD76-91B7-4043-8A9E-54767D3B20B5

Q30899557-33DA91B1-73C4-46B3-A8A7-A069F08C5ABB

Q30899557-38AFAF40-F97F-4864-97A5-2B0C7492B79A

Q30899557-39BC97A3-EEB8-4C32-A395-1F6BEC19F2B1

Q30899557-3BAB062B-AF06-451F-AF79-342E86409000

Q30899557-3E103543-5271-4FE6-8F87-57835504198D

P304

Q30899557-A884AA63-EDFC-4FC9-A624-1D65956530AC

P31

Q30899557-029F5F73-D897-43A6-BC77-C4AAC6A49C14

P356

Q30899557-CDA58369-AA03-4CEF-B614-5A95398187BF

P407

Q30899557-278488FA-C5C4-4297-B2E3-852D9C75C764

P433

Q30899557-9D6C080E-C502-469B-9CB1-97D766D67DCD

P478

Q30899557-8BA8517E-5CA2-4D44-8963-DCD6E77F9FED

P50

Q30899557-0A58E402-27DB-4DCE-949F-73271B0F1C52

Q30899557-18F02A6A-5A38-4A61-9496-985594D1A609

Q30899557-2864C44E-3A20-4B70-B59C-D35710473B40

Q30899557-55DD998D-329C-4966-989A-1E2BCAEFF451

Q30899557-7C08A6CA-F9D9-4A12-BEED-C2CD46454B49

Q30899557-A3F3DA71-8F90-4066-8639-F14A0A4C5883

Q30899557-ED41D904-8184-43DC-AC39-B2CDCCA7E370

P577

Q30899557-443A15E7-A21B-48CE-9277-5528FFD9B5E9

P5875

Q30899557-022CABEC-DADF-4713-BCC6-8D8B7B993D32

P698

Q30899557-16951A4B-4432-4070-93A6-B384B12FC335

P921

Q30899557-6CA2D5B6-FFFE-4466-9EBE-6025D495E1CF

P932

Q30899557-20A2E814-0BFF-4370-9A1A-2505FEFFEB81

P356

ONCOTARGET.2901

P1433

P1476

Immunological data from cancer ...... tility for tumor immunotherapy

@en

P2093

Ari Ristimäki

http://www.w3.org/2001/XMLSchema#string

Dirk M Nettelbeck

http://www.w3.org/2001/XMLSchema#string

Ilkka Liikanen

http://www.w3.org/2001/XMLSchema#string

Johan Lundin

http://www.w3.org/2001/XMLSchema#string

Juuso Juhila

http://www.w3.org/2001/XMLSchema#string

Kaarina Partanen

http://www.w3.org/2001/XMLSchema#string

Kalevi Kairemo

http://www.w3.org/2001/XMLSchema#string

Nina Linder

http://www.w3.org/2001/XMLSchema#string

Otto Hemminki

http://www.w3.org/2001/XMLSchema#string

Suvi Parviainen

http://www.w3.org/2001/XMLSchema#string

P2860

The Hallmarks of Cancer

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

BioMart and Bioconductor: a powerful link between biological databases and microarray data analysis.

beadarray: R classes and methods for Illumina bead-based data.

Replicative adenoviruses for cancer therapy.

Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.

Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.

P304

4467-4481

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.2901

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Akseli Hemminki

Matti Kankainen

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272839845

http://www.w3.org/2001/XMLSchema#string

P698

25714011

http://www.w3.org/2001/XMLSchema#string

P921

P932

4414204

http://www.w3.org/2001/XMLSchema#string